^
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive
:
A1
No biomarker
CLL
rituximab + ibrutinib
Sensitive
:
A1
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
CLL
ICP-022
Sensitive
:
A1
CD20 expression
CLL
rituximab-arrx
Sensitive
:
A1
TP53 mutation
CLL
venetoclax
Sensitive
:
A1
No biomarker
CLL
Truxima (rituximab biosimilar)
Sensitive
:
A1
No biomarker
CLL
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
CLL
Ruxience (rituximab biosimilar)
Sensitive
:
A1
No biomarker
CLL
venetoclax + rituximab
Sensitive
:
A1
Chr del(17p)
CLL
venetoclax
Sensitive
:
A1
No biomarker
CLL
zanubrutinib
Sensitive
:
A1
No biomarker
CLL
ibrutinib
Sensitive
:
A1
No biomarker
CLL
ibrutinib + obinutuzumab
Sensitive
:
A1
No biomarker
CLL
obinutuzumab
Sensitive
:
A1
No biomarker
CLL
rituximab
Sensitive
:
A1
No biomarker
CLL
ofatumumab
Sensitive
:
A1
CD20 positive
CLL
rituximab
Sensitive
:
A1
No biomarker
CLL
venetoclax
Sensitive
:
A1
No biomarker
CLL
rituximab/hyaluronidase
Sensitive
:
A1
Chr del(17p)
CLL
ibrutinib
Sensitive
:
A1
No biomarker
CLL
obinutuzumab + acalabrutinib
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our